Abstract: The invention relates to a workspace wall (1) for placement on a desk to reduce noise within a noise reduction area (7) in an operating orientation (11). The workspace wall (1) comprises a main wall element (3), at least one wing panel (4), optionally at least one sound detection element (21) for detecting a sound signal input (12), and at least one sound generating device (22), preferably for active noise reduction and/or a passive noise reduction element (20). The at least one sound generating device (22) and/or the passive noise reduction element (20) is configured to reduce the level of noise within the noise reduction area (7). (FIG.

Abstract: Compounds, e.g., radioimmunoconjuguates including a chelating moiety or a metal complex thereof, a linker, and an EGFRVIII targeting moiety. Pharmaceutical compositions of such compounds and methods of treatment for conditions. e.g., cancer, using such compounds or pharmaceutical compositions.

Abstract: Antigen-binding agents such as humanized antibodies or antigen-binding fragments thereof, that specifically bind to epidermal growth factor receptor variant III (EGFRvIII) are provided. The EGFRVIII-specific humanized antibodies or antigen-binding fragments thereof may be used for the treatment of cancer.

Abstract: Described herein are compositions and methods to modulate gene expression without permanently editing the genome. The compositions and methods may be useful to treat neurological diseases and pain.

Abstract: Provided herein are compositions and methods for treating metabolic disorders, such as hepatic steatosis, adipose tissue dysfunction, and insulin resistance. Small interfering RNAs (siRNAs) targeting LPS-binding protein (LBP) that include unlocked nucleotides (UNA) and their therapeutic applications for the treatment of metabolic disorders are provided herein.

Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.

Abstract: An occlusive device, occlusive device delivery system, method of using, and method of delivering an occlusive device, and method of making an occlusive device to treat various intravascular conditions is described.

Abstract: An occlusive device, occlusive device delivery system, method of using, and method of delivering an occlusive device, and method of making an occlusive device to treat various intravascular conditions is described.

Abstract: Antigen-binding agents such as antibodies or antigen-binding fragments thereof, chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTEs) and the like that specifically bind to epidermal growth factor receptor variant III (EGFRvIII) are provided. The EGFRvIII-specific antibodies or antigen-binding fragments, CARs and BiTEs thereof may be used for the treatment of cancer. Antibody drug conjugates targeting EGFRvIII-expressing cells are particularly contemplated.

Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.

Abstract: The present invention pertains to genetically modified plants, particularly maize, sorghum and rice, with an all pistillate or all staminate phenotype and methods of the same. The survival of functional pistils in maize requires the action of the sk1 gene. SK1 encodes a glycosyltransferase (GT) that protects pistils from tasselseed-mediated cell death. sk1-dependent pistil protection at a developing floret gives rise to stamen arrest at the same floret, and so determines the pistillate floral fate. This is the first single gain-of-function gene known to control sexuality. The present invention further provides a direct strategy to extend hybrid technologies to related cereals such as sorghum and rice. Tasselseed and silkless genes represent major sex determination genes in maize, a pathway that permits the efficient production of hybrid seed and the associated benefits of heterosis-increased yield, resistance to pathogens, etc.

Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.

Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.

Abstract: An occlusive device, occlusive device delivery system, method of using, and method of delivering an occlusive device, and method of making an occlusive device to treat various intravascular conditions is described.

Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.

Abstract: An occlusive device, occlusive device delivery system, method of using, and method of delivering an occlusive device, and method of making an occlusive device to treat various intravascular conditions is described.

Abstract: The present invention provides a method for the treatment or prophylaxis of bacterial infections by administering to a subject in need thereof an effective amount of a compound of formula.

Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections: R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2??(I):

Abstract: Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins.

Abstract: The invention relates to a generator of electrical current by movement and induction by means of permanent magnets and resonant coils according to an envelope housing a circular solid element in the form of a rotor in which a variable magnetic flux is generated by incorporating thirty-eight permanent and rectangular magnets arranged such that they are radially aligned on the outer periphery of said rotor, and rotating inside a stator which has an annular shape and is hollow so as to carry out the cooling on the inside thereof, containing seventy-six idle coils which are regularly distributed and between which resonant capacitors and coils are alternated with non-resonant coils, arranged specifically three millimetres from the magnets, from which electrical current is generated with a very high efficiency.